Experimental drug aims to supercharge radiation against glioblastoma
NCT ID NCT06359379
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested a drug called ropidoxuridine, taken as a pill, to see if it could make radiation therapy more effective for people with a newly diagnosed, aggressive type of brain cancer (glioblastoma). The study enrolled 30 patients with a specific genetic marker (unmethylated MGMT promoter). Unfortunately, the trial was terminated early, so we have limited data on whether the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ropidoxuridine
What this could lead to
If it worked, this could point toward a way to make radiation more effective against a tough brain cancer.
What could go wrong
This trial was terminated early, so results are limited. It was a small Phase 2 study, and the drug may not improve outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212, United States
-
John Theurer Cancer Center at the Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Miami Cancer Institute
Miami, Florida, 33176, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States